NEA
SelectiveFiled to raiseTimonium, MDBiotechnology, Healthcare, PharmaceuticalsLast fund filed 2025
7 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| New Enterprise Associates 19Filed to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| NEA 19 Access FundFiled to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| NEA 19 Venture Growth EquityFiled to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| NEA Secondary Opportunity Fund | July 2024 | $468M | $468M | 60 |
| Point 406 Ventures Opportunities Fund IIIFiled to raise in 2024, with no closing reported yet. | 2024 | $50M | $0 | 0 |
| New Enterprise Associates 18 | December 2021 | $2.9B | $2.8B | 271 |
| NEA 18 Venture Growth Equity | December 2021 | $3.7B | $2.3B | 244 |
| Connect Ventures IFiled to raise in 2020, with no closing reported yet. | 2020 | Indefinite | $0 | 0 |
| New Enterprise Associates 17Filed to raise in 2019, with no closing reported yet. | 2019 | $3.6B | $0 | 0 |
| New Enterprise Associates 16Filed to raise in 2017, with no closing reported yet. | 2017 | $3B | $0 | 0 |
| NEA 15 Opportunity Fund | April 2015 | $350M | $350M | 9 |
| New Enterprise Associates 15Filed to raise in 2015, with no closing reported yet. | 2015 | $2.5B | $0 | 0 |
| New Enterprise Associates 14Filed to raise in 2012, with no closing reported yet. | 2012 | $2.3B | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
20 partners are named across this firm’s filings, 7 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Mohamad Makhzoumi | Selective | Digital health, Healthcare services, Biotech & pharma | 13 | 2 |
| Edward Mathers | Slowing | Biotech & pharma | 25 | 1 |
| Ali Behbahani | Quiet | None listed | 21 | 0 |
| Carmen ChangNot on the current fund | Quiet | Education, Logistics & supply chain, Robotics & hardware | 4 | 0 |
| David MottNot on the current fund | Quiet | Biotech & pharma | 12 | 0 |
| Forest BaskettNot on the current fund | Quiet | Cybersecurity, Manufacturing & industrials, Telecom & networking | 10 | 0 |
| Harry WellerNot on the current fund | Quiet | Enterprise software, Sales & marketing tech, AI & machine learning | 15 | 0 |
| Jon SakodaNot on the current fund | Quiet | Developer tools & infrastructure, Cybersecurity, E-commerce & marketplaces | 7 | 0 |
| Joshua MakowerNot on the current fund | Quiet | Medical devices, Biotech & pharma, Robotics & hardware | 17 | 0 |
| Krishna KolluriNot on the current fund | Quiet | Robotics & hardware, Telecom & networking, Crypto & web3 | 8 | 0 |
| Liza Landsman GoldNot on the current fund | Quiet | None listed | 0 | 0 |
| M. BarrettNot on the current fund | Quiet | Biotech & pharma, Medical devices | 4 | 0 |
| Paul Walker | Quiet | Biotech & pharma, Developer tools & infrastructure, Enterprise software | 7 | 0 |
| Payal DivakaranNot on the current fund | Quiet | Developer tools & infrastructure, Digital health, Healthcare services | 4 | 0 |
| Peter BarrisNot on the current fund | Quiet | Enterprise software, Cybersecurity, Robotics & hardware | 10 | 0 |
| Peter SonsiniNot on the current fund | Quiet | Data & analytics, Developer tools & infrastructure, Enterprise software | 20 | 0 |
| Ravi ViswanathanNot on the current fund | Quiet | Enterprise software, Consumer apps & internet, Data & analytics | 7 | 0 |
| Rick Yang | Quiet | Medical devices, Sales & marketing tech, AI & machine learning | 12 | 0 |
| Scott Sandell | Quiet | Cybersecurity, Enterprise software, Climate & energy | 12 | 0 |
| Tony Florence | Quiet | E-commerce & marketplaces, Biotech & pharma, AI & machine learning | 17 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of NEA’s own portfolio companies, based on 211 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of NEA’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Rivervest | 6 | Allakos, Amplyx Pharmaceuticals, Curzion Pharmaceuticals, Lumena Pharmaceuticals, Mirum Pharmaceuticals, Reneo Pharmaceuticals |
| Benchmark | 5 | ENGINE YARD, Heap, LITHIUM TECHNOLOGIES, Placester, ScoutRFP |
| Bessemer Venture Partners | 5 | Bright Health, Docent Health, LogicNow S.A., Raise Marketplace, WellTok |
| AH Games | 3 | Anyscale, Databricks, Sisu Data |
| Andreessen Horowitz | 3 | Anyscale, Databricks, Sisu Data |
| Canvas Ventures | 3 | Branch Metrics, Enigma Technologies, Transfix |
| Construct Capital | 3 | Curalate, Onshape, Upskill |
| Lightspeed Affiliates | 3 | Cohere Technologies, MAPR TECHNOLOGIES, Tintri |
| Lightstone Singapore | 3 | ExploraMed NC7, Foundry Therapeutics 1, Moximed |
| Orbimed Asia Partners | 3 | Adaptimmune, IMARA, MBX Biosciences |
| Orbimed Genesis | 3 | Adaptimmune, IMARA, MBX Biosciences |
| Pivotal bioVenture Partners | 3 | Ceterix Orthopaedics, Eargo, Ra Pharmaceuticals |
| Sofinnova Venture Partners | 3 | Amplyx Pharmaceuticals, Inozyme Pharma, SYNLOGIC |
| Westlake Biopartners | 3 | 3-V Biosciences, Ceterix Orthopaedics, TESARO |
| Battery Ventures | 2 | GoEuro, StreamSets |
A shared board seat: a company where filings name a NEA partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.